| Type 2 Diabetes Mellitus |
1 |
1 |
| Heart Failure (HF) |
0 |
0.73 |
| Cardiovascular Risk Management |
0 |
0.66 |
| Renal Disease |
0 |
0.56 |
| Cardiovascular disease |
0 |
0.51 |
| Heart |
0 |
0.51 |
| Bipolar Disorder |
0 |
0.35 |
| Cardiovascular Imaging |
0 |
0.31 |
| Scan |
0 |
0.31 |
| Cerebrovascular Accident |
0 |
0.21 |
| Cognition |
0 |
0.2 |
| Geriatrics |
0 |
0.2 |
| Concerns of Elderly |
0 |
0.17 |
| GLP-1 Receptor Agonist |
0 |
0.17 |
| Depression |
0 |
0.15 |
| Cognitive Impairment |
0 |
0.14 |
| Lipids Management |
0 |
0.14 |
| Amputation |
0 |
0.1 |
| Bipolar Depression |
0 |
0.1 |
| Clinical Guidelines |
0 |
0.1 |
| Ejection Fraction |
0 |
0.1 |
| Frailty |
0 |
0.1 |
| Impairment |
0 |
0.1 |
| Information Management |
0 |
0.1 |
| Kidney |
0 |
0.1 |
| Mental Illness |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| SGLT2 Inhibitor |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Mild Cognitive Impairment |
0 |
0.07 |
| Schizophrenia |
0 |
0.07 |